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Abstract
Background: Coagadex is a high- purity plasma- derived factor X concentrate (pdFX) 
developed to treat hereditary factor X deficiency (FXD).
Objective: Evaluate the efficacy and safety of pdFX administered to patients with 
hereditary FXD.
Methods: This was an open- label, multicenter, retrospective analysis of patients re-
ceiving pdFX for compassionate use. Efficacy end points included treatments admin-
istered, the number and treatment of bleeds, and investigator assessments. Adverse 
drug reactions (ADRs) were monitored.
Results: Fifteen patients were included: seven received routine prophylaxis, seven re-
ceived	on-	demand	treatment,	and	one	alternated.	Most	were	aged	≥12	years	(n	=	13)	
and	had	severe	hereditary	FXD	(n	=	12).	The	median	follow-	up	time	was	19.2	months	
(range, 3.5- 48.8). The number of infusions per patient per month was higher for the 






In an overall assessment, investigators rated pdFX as excellent for 14 patients (93.3%) 
and good for 1 patient (6.3%). No ADRs or safety concerns were reported.
Conclusions: This analysis supports the use of pdFX as a safe, effective treatment for 
hereditary FXD. Routine prophylaxis with pdFX may reduce bleed frequency.
K E Y W O R D S
blood coagulation disorders and inherited, compassionate use trials, factor X deficiency, 
retrospective studies, treatment outcome
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Essentials
• Plasma- derived factor X (pdFX) is used to treat hereditary factor X deficiency.
• This was an open- label, retrospective analysis of compassionate use of pdFX in 15 patients.
• Overall, investigators rated pdFX as excellent for 14 patients and good for 1 patient.
• No adverse drug reactions or safety concerns were reported.
1  |  INTRODUC TION
Hereditary factor X deficiency (FXD) is a rare autosomal recessive 
bleeding disorder that affects approximately 1:1 000 000 individuals 
worldwide.1,2 Bleeding patterns are similar to those seen in hemo-
philia A and B and may involve menorrhagia for female patients1 or 
bleeds in the joints, muscles, or mucous membranes for both male 
and female patients.1,3 FXD severity can vary and is classified by 
the endogenous level of factor X (FX) in the plasma; at the time of 
this analysis, patients with FX activity (FX:C) of 6 to 10, 1 to 5, and 
<1 U/dL were considered mildly, moderately, and severely affected, 
respectively,4 though changes to this rating system have been 
suggested.5
Though treatment guidelines now recommend using single- 
factor concentrate whenever possible for rare bleeding disorder 
management,6,7 patients with hereditary FXD experiencing bleeds 
have historically been treated with fresh frozen plasma (FFP) and 
prothrombin complex concentrates (PCCs).8 These treatment op-
tions are not specific to FXD, and levels of some factors in PCCs 
may be inconsistent.9 The volume of FFP necessary to treat a bleed 
may lead to blood volume overload and the infusion of unnecessary 
factors with either treatment may increase the risks of thrombosis 
and/or anaphylaxis.1,4,9
Recently, a high- purity plasma- derived FX concentrate (pdFX; 
Coagadex, Bio Products Laboratory, Elstree, UK), manufactured 
from plasma obtained from healthy US donors who have passed 
viral screening tests, was developed and licensed for use in the 
United States, the United Kingdom, and the European Union. In 
clinical trials, pdFX demonstrated efficacy when used for short- 
term prophylaxis, on- demand treatment,10 and surgical coverage11 
among adults with hereditary FXD, as well as when used for pro-
phylactic and on- demand treatment in children aged <12 years.12 
No adverse events considered related to pdFX treatment and 
no inhibitor development were observed in these clinical tri-
als.10- 12 Many of the patients included in the previous clinical trials 
also received pdFX on a compassionate- use basis. Data from these 
patients can provide additional information on pdFX use in real- 
world settings, including data on efficacy during various treatment 
regimens and safety during long- term use (up to 4 years). In this 
retrospective analysis, the efficacy and safety of pdFX was further 
evaluated in patients with hereditary FXD. pdFX was administered 
on a compassionate- use basis as part of routine prophylaxis, on- 
demand treatment, short- term prevention, or a perisurgical cov-
erage regimen.
2  |  MATERIAL S AND METHODS
2.1  |  Study design
This was an open- label, multicenter, international, retrospective 
analysis of the use of pdFX given on a compassionate- use basis from 
March 30, 2011, through December 31, 2015. Data were collected 
retrospectively from 12 sites across five countries: Germany, Spain, 
Turkey, the United Kingdom, and the United States.
Patients were eligible if they had hereditary FXD, regardless of 
age or FXD severity, and had received pdFX on a compassionate- use 
basis. The study protocol was approved by the appropriate indepen-
dent ethics committees, and all adult patients provided written in-
formed consent. For minors, written informed consent was provided 
by a parent or guardian and, where appropriate, assent was provided 
by the child.
2.2  |  Treatments
pdFX is a lyophilized powder that comes in single- use vials of ap-
proximately 250 or 500 IU. After reconstitution in sterile water, 
the resulting concentration is approximately 100 IU/mL and is ad-
ministered via intravenous infusion at a rate of 10 mL/min (20 mL/
min maximum). The potency of FX activity in pdFX concentrate, 
measured in IU, is determined using an in vitro chromogenic assay 
and an FX concentrate reference standard calibrated against the 
World Health Organization Third International Standard for Blood 
Coagulation Factors II and X, Concentrate.
Patients received pdFX as routine prophylaxis, on- demand treat-
ment, short- term prevention, and/or perisurgical hemostatic cover. 
Routine	prophylaxis	was	defined	as	a	dose	of	≥25	IU/kg	at	least	once	
weekly	for	patients	aged	≥12	years.	Short-	term	prevention	was	de-
fined as less frequent dosing or doses <25 IU/kg per infusion. Across 
all groups, however, the specific dosing regimen was left to the dis-
cretion of the investigator and individually tailored to the patient.
2.3  |  Assessments
Primary efficacy analyses were completed on a per- subject basis. For 
routine prophylaxis, the average number of bleeds per year and per 
month (including severity, location, and cause) and the total dose per 
year and per month were evaluated. For patients receiving on- demand 
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treatment, investigators provided a retrospective assessment of pdFX 
efficacy (effective, not effective, or unknown) in treating each bleed, 
as well as the dose of pdFX used. “Effective” was defined as achieving 
hemostasis with the expected number of pdFX doses for the severity 
of the bleed. Investigators also provided a retrospective assessment of 
the overall efficacy (excellent, good, poor, or unassessable) of pdFX. 
Efficacy was rated as “excellent” (regularly met or exceeded expecta-
tions), “good” (less than expected but still adequate), “poor” (did not 
provide satisfactory hemostasis), or “unassessable” (could not be as-
sessed, eg, no bleeds requiring pdFX occurred during the analysis pe-
riod or another replacement therapy was given for all bleeds during 
the analysis period). Additional assessments included the total dose, 
the number of infusions, the average dose per infusion, and the num-
ber of exposure days per subject. When possible, bleed severity was 
classified as major or minor. Severe gastrointestinal bleeding, intracer-
ebral hemorrhage, severe hemarthrosis, major menorrhagia, and large 
and/or complicated muscle hematoma were defined as major bleeds. 
Epistaxis, gum bleed, mild menorrhagia, and superficial hematoma 
were defined as minor bleeds.
Safety was assessed on the basis of the incidence of adverse 
drug reactions (ADRs) and serious adverse reactions. When avail-
able, FX activity (FX:C) trough levels and tolerability were assessed.
2.4  |  Statistical analyses
Due to inclusion criteria, the per- protocol population (all patients 
who consented) and the safety/intent- to- treat population (all pa-
tients who received at least one dose of pdFX) were identical. Two 
primary subpopulations were analyzed: the routine prophylaxis pop-
ulation and the on- demand treatment population. Two additional 
subpopulations were analyzed: the short- term preventative treat-
ment population and the perisurgical coverage population. (All of 
these patients were also counted in either the routine prophylaxis 
population or the on- demand population.)
3  |  RESULTS
3.1  |  Patients
Fifteen patients who received pdFX for compassionate use agreed 
to be included in the analysis. Seven patients received pdFX as rou-
tine prophylaxis, seven used pdFX as on- demand treatment, and one 
alternated between routine prophylaxis and on- demand treatment. 
Three patients on routine prophylaxis also used pdFX for perisurgi-
cal hemostatic cover. Six patients used pdFX for short- term preventa-
tive use, three were receiving routine prophylaxis, two were receiving 
on- demand treatment, and one alternated between both. Individual 
patient characteristics are provided in Table 1. Most patients were 
aged	≥12	years	(n	=	13)	and	had	severe	hereditary	FXD	(n	=	12).	All	
13	patients	aged	≥12	years	had	already	been	administered	pdFX	as	
part of a previous clinical trial.10 The two patients aged <12 years were 
administered pdFX in a subsequent pediatric clinical trial.12 This report 
does not include data on exposure or outcomes that occurred during 
these clinical trials.
3.2  |  Treatments administered
The median (range) duration of compassionate use among all 
15 patients was 19.2 (3.5- 48.8) months, or approximately 1.6 
TA B L E  1 Patient	characteristics
Patient number




Bleeds in the 12 months 
preceding the study period
Time on study, 
months
Treatment type(s) 
received in the study
1 23 Male <1 1– 5 16.1 RP, STP
2 21 Male <1 >10 24.2 RP
3 32 Female <1 >10 21.7 RP, OD, surgery
4 17 Male <1 1– 5 20.1 RP, OD, STP, surgery
5 22 Male <1 6– 10 28.5 RP, OD, STP
6 15 Female <5 >10 36.5 RP, STP
7 6 Female 4 0 48.8 RP
8 1 Male 2 6– 10 12.9 RP, surgery
9 37 Male <1 1– 5 18 OD
10 43 Female <1 1– 5 19.2 OD
11 22 Female <1 >10 4.1 OD
12 17 Female <1 >10 3.5 OD
13 21 Female <1 >10 6.4 OD
14 13 Male 1 >10 15.7 OD, STP
15 14 Female <1 >10 28.3 OD, STP
Abbreviations: FX:C, factor X activity; OD, on demand; pdFX, plasma- derived factor X concentrate; RP, routine prophylaxis; STP, short- term 
prevention.
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(0.3- 4.0) years. This amounts to 304.1 subject- months (or 25.2 
subject-	years)	of	exposure	from	1373	infusions.	Overall,	the	median	
(range) pdFX per patient per month was 55.9 (2.5- 540.2) IU/kg, with a 
median	total	amount	of	pdFX	per	patient	of	1462.7	(46-	26	357)	IU/kg,	
administered over a median of 49 (2- 492) infusions. The monthly 
pdFX	 was	 lower	 for	 patients	 aged	 ≥12	 years	 (median	 [range],	
37.5	[2.5-	155.7]	IU/kg	over	2.0	[0.1-	6.9]	infusions)	than	for	patients	
aged	 <12	 years	 (median	 [range],	 517.0	 [493.9-	540.2]	 IU/kg	 over	
10.1 [10.1- 10.2] infusions).
As expected, patients receiving routine prophylaxis received, on 
average, larger and more frequent doses of pdFX than patients in the 
other treatment groups (Table 2). A total of 1239 prophylactic infu-
sions were administered to eight patients: three received infusions 
every 3 days, four received weekly infusions (including two patients 
who briefly switched to dosing every 2 days), and one received pdFX 
every 15 days, per individual investigator’s discretion. The 2 patients 
aged <12 years received a larger dose per infusion (median [range], 
51.1	[48.5-	53.6]	IU/kg)	than	the	six	patients	aged	≥12	years	(median	
[range],	27.2	[21.9-	29.9]	IU/kg).	Of	the	three	patients	who	also	received	
pdFX perisurgically, two underwent a dental procedure and required 
only	one	presurgical	pdFX	 infusion	each	 (27.1	and	28.5	 IU/kg).	The	
third perisurgical patient underwent an implanted port insertion and 
required six infusions to maintain hemostasis (two infusions on the day 
of	the	surgery	totaling	72.8	IU/kg	and	four	infusions	of	48.5	IU/kg	on	
days 1, 2, 3, and 5). All patients in the on- demand treatment group 
(n	=	8)	experienced	at	 least	one	bleed.	For	 the	six	patients	who	re-
ceived short- term preventative treatment, the number of exposure 
days ranged from 1 to 6, with a median of 3.5 exposure days and a col-
lective total of 21 exposure days. The median (range) dose per infusion 
was	23.2	(7.3-	57.1)	IU/kg.
3.3  |  Bleeding episodes
Eighty- eight bleeds, with a median (range) duration of 1 (1- 22) days, 
were	 reported	 by	 12	 patients,	 all	 of	 whom	 were	 ≥12	 years	 old	
(Figure 1). This amounts to a median of 5.5 bleeds per patient and 
a monthly per- patient bleed rate of 0.4. Of the 88 bleeds, 41 had a 
recorded severity classification, with 34 of 41 classified as minor. 
Seventy- nine bleeds were treated with pdFX across 99 exposure 
days.	The	median	(range)	dose	per	infusion	was	22.0	(13.6-	29.7)	IU/kg.	
Investigators rated all treatments as effective. Information regarding 
treatments for bleeds not treated with pdFX was not recorded.
Among the eight patients in the routine prophylaxis population, 
17	bleeds	were	reported	by	four	patients	(all	aged	≥12	years)	(Table	3).	
The overall median bleed rate per patient was 1 bleed per patient, 
equivalent to 0.04 bleeding episodes per patient per month. For the 
four patients on prophylaxis who reported bleeds, the median bleed 
rate was 3.5 bleeds per patient, or 0.1 bleeding episodes per patient 
per month. More specifically, these four patients experienced 2, 3, 4, 
and 8 bleeds while being treated with pdFX once per week, once every 
3 days, once every 15 days, and once per week, respectively. All four 
patients had severe FXD, and three of the four patients experienced 
1 major bleed; in the patient with 4 bleeds, all 4 were rated as minor 
(Table	3).	 Ten	of	 the	17	 total	 bleeds	were	 treated	with	pdFX,	with	
a	median	(range)	dose	of	28.4	(21.9-	29.7)	IU/kg	per	infusion.	Of	the	
four patients on prophylaxis who did not experience bleeds, two were 
aged <12 years, one with severe FXD and one with moderate FXD; 
they received pdFX once every 3 days for an average of 540.1 IU/
kg	and	473.2	IU/kg	per	month,	respectively.	The	two	patients	aged	
≥12	years	who	did	not	bleed	on	prophylactic	therapy	had	severe	FXD;	
one was treated once a week, followed by once every 2 days and then 
once a week, for an overall dose of 148.5 IU/kg per month, and the 
other was treated once a week for 5 months, followed by a 10- month 
period of on- demand treatment and then once every 2 weeks for 
7	months,	for	an	overall	dose	of	37.5	IU/kg	per	month.
The	remaining	71	bleeds	were	reported	by	the	on-	demand	popu-
lation (Table 3), and 69 of these bleeds were treated with pdFX. This 
includes 6 bleeds that occurred during approximately 10 months 
of on- demand treatment for the patient who alternated between 
routine prophylaxis and on- demand treatment. This patient did not 
experience any bleeds during approximately 12 months of routine 
prophylaxis. The resulting overall bleed rate for the on- demand pop-
ulation was 8.9 bleeds per patient, equivalent to 0.8 bleeding epi-
sodes per patient per month. The minimum number of bleeds in any 
patient was 2, occurring in 1 patient and separated by 18 months, 
whereas the maximum number of bleeds was 26, occurring in one 
patient over 28.3 months. The median (range) pdFX dose per infu-
sion	was	20.0	(13.6-	27.7)	IU/kg.
There were no bleeds recorded for patients receiving short- term 
preventative treatment, and no excessive bleeding was reported 
during surgery.
3.4  |  Investigator assessments of efficacy
For 14 patients, investigators assessed the overall efficacy of pdFX 
during compassionate use as excellent, defined as “efficacy of pdFX 
regularly [having] met or exceeded expectations.” For the remaining 
patient, the investigator rated the overall efficacy of pdFX as good, 
defined as “efficacy of pdFX less than expected, but still adequate.”
3.5  |  FX activity
Predose FX:C was recorded 18 times from four patients, all of whom 
were receiving prophylactic treatment. Postdose FX:C was recorded 
eight times from three patients (Table 4). No patient had both 
pre- and postdose measurements, so incremental recovery could 
not be calculated. The overall median (range) predose FX:C was 
6.0 (2.0- 54.0) IU/dL, with FX:C <5.0 IU/dL for 6 of the 18 predose 
measurements. In contrast, the median (range) postdose FX:C was 
76.5	(46.0-	114.0)	IU/dL,	and	no	patient	was	severely	deficient	after	
dosing.	Predose	FX:C	was	higher	for	patients	aged	≥12	years	(median	
[range], 29.5 [5.0- 54.0] IU/dL) than for patients aged <12 years (6.0 
[2.0- 40.0] IU/dL; Table 4). Likewise, postdose FX:C was higher for 
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Mean (SD) 91.5 (130.1) 154.9 (150.6) 11.0	(7.6) 3.5 (1.9) 2.7	(2.9)
Median (range) 49 (2- 492) 98.5 (39- 492) 9.5 (2- 26) 3.5 (1- 6) 1 (1- 6)
Number of infusions/subject/month
Mean (SD) 3.7	(3.4) 5.6 (3.2) 0.9	(0.7) 0.2 (0.1) NA
Median (range) 2.1 (0.1- 10.2) 5.4 (1.4- 10.1) 0.8 (0.1- 2.3) 0.2 (0.0- 0.3) NA
Total dose/subject, IU/kg
Mean (SD) 3417.3	(6648.3) 5985.2 (8425.1) 237.1	(192.9) 120.9 (121.9) 107.5	(138.1)
Median (range) 1462.7	(46-	26,	357) 2527.2	(1069-	26,	357) 149.1	(46-	571) 92.8 (14.5- 342.6) 28.5	(27.1-	267.0)
Dose/infusion/subject, IU/kg
Mean (SD) NR 32.5 (11.8) 20.5 (5.1) 28.9	(17.2) 33.4	(9.7)
Median (range) NR 27.9	(21.9-	53.6) 20.0	(13.6-	27.7) 23.2	(7.3-	57.1) 28.5	(27.1-	44.5)
Dose/subject/month, IU/kg
Mean (SD) 124.6 (168.3) 206.2 (190.4) 18.2 (10.8) 5.2 (4.6) NA
Median (range) 55.9 (2.5- 540.2) 135.5	(37.5-	540.2) 18.2	(2.5-	37.5) 4.8 (0.63- 12.1) NA
Dose/subject/year, IU/kg
Mean (SD) 1504.6 (2032.6) 2490.3 (2299.1) 220.1 (130.0) 62.9	(55.7) NA
Median (range) 674.7	(30.6-	6522.3) 1635.6 (453.1- 6522.3) 220.0 (30.6- 452.2) 58.2	(7.6-	146.2) NA
Abbreviations: NA, not applicable; NR, not reported; pdFX, plasma- derived factor X concentrate; SD, standard deviation.
F I G U R E  1 Characteristics	of	bleeding	episodes	by	(A)	number	of	subjects	exhibiting	the	defined	type	of	bleed	(n	=	12)*	and	(B)	number	of	
bleeds	(n	=	88).	*Patients	may	have	reported	more	than	1	type	of	bleed	severity,	cause,	or	location.	**Included	miscarriage	(occurred	twice	
in	one	subject),	cut	on	right	hand	(occurred	once	in	one	subject),	and	postpartum	bleed	(occurred	once	in	one	subject).	***Included	left	leg	
or right leg (occurred four times in the same subject), renal hemorrhage (occurred once in one subject), soft tissue of left forearm (occurred 
once in one subject), subcutaneous (occurred three times in one subject), subdural hematoma and external ear (each occurred once in the 
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patients	aged	≥12	years	(median	[range],	103.0	[92.0-	114.0]	IU/dL)	
than for patients aged <12 years (66.0 [46.0- 84.0] IU/dL).
3.6  |  Safety
No ADRs, including inhibitor development, infusion- site reactions, 
thromboembolic events, or other safety concerns or tolerability is-
sues, were reported during the study. Likewise, no deaths or seri-
ous adverse drug reactions were reported. Two patients reported 
successful pregnancies and childbirths, with no abnormal bleeding 
complications and no efficacy or safety concerns. Details regarding 
these patients have previously been published.13
4  |  DISCUSSION
In this retrospective analysis, data were collected on the efficacy 
and safety of long- term compassionate use of pdFX in 15 patients 
with hereditary FXD. The median treatment duration was 1.6 years, 
with a maximum duration of 4 years. All patients received pdFX as 
either routine prophylaxis or an on- demand treatment. At times, 
some patients used a short- term preventative or a perisurgical cov-
erage	regimen	instead.	Overall,	patients	aged	≥12	years	received	a	
lower dose and fewer infusions than patients aged <12 years. pdFX 
was used to treat most of the bleeds that occurred during the study 
period, with effectiveness in all cases, per investigators. Even with 
data on up to 4 years of pdFX treatment, no ADRs, tolerability is-
sues, or other safety concerns were reported.
Dosing for patients included in this analysis was at the discretion 
of the investigator (data were collected retrospectively). As might be 
expected based on the inter- and intrapatient variability of FXD dis-
ease course, there were large variations in the number of infusions 
(2-	492)	and	the	total	dose	per	subject	 (46-	26,	357	IU/kg).	The	ob-
served variability in dosing may be explained in part by the age range 
of the included patients (1- 43 years), as younger patients have been 
shown to have a lower incremental recovery than older patients and 
thus require a higher dose.12,14 In a study of patients aged <12 years, 
incremental recovery was significantly lower for patients aged 0 
to 5 years than for those aged 6 to 11 years.12 Furthermore, in the 
same study, patients aged <12 years had a lower incremental recov-
ery	than	those	 in	a	separate	study	of	patients	aged	≥12	years.10,12 
Accordingly, the pdFX product label now recommends higher dos-
ing	 for	 patients	 aged	 <12	 years	 than	 for	 those	 aged	 ≥12	 years.14 
However, in the current analysis, the effects of age on factor half- life 
or incremental recovery could not be assessed. Doses were calcu-
lated to the nearest 0.1 mL, and any surplus solution was discarded. 
Clinicians should consider using a similar method to ensure that 
doses given to pediatric patients do not exceed the maximum daily 
dose recommended in the prescribing information (60 IU/kg).
Patients who received pdFX as routine prophylaxis had a lower 
bleed rate (0.04 bleeds per month) than patients who received only 
on- demand treatment (0.8 bleeds per month). The patient who 
switched between prophylactic and on- demand treatment received 
30.8 IU/kg weekly and then 23.1 IU/kg every 2 weeks. This lower 
dose was the same as doses used to treat bleeding episodes that oc-
curred during the on- demand treatment period (with the exception of 
a major central nervous system bleed for which the patient received 
12 doses of treatment in the week following the event). This patient 
experienced no bleeds on routine prophylaxis and 6 bleeds during on- 
demand treatment, suggesting that this prophylactic dose was suf-
ficient to prevent bleeding. This may be due to an increase in FX:C 
with prophylactic treatment, since greater FX:C is associated with 
reduced clinical bleeding severity.15 In a separate prospective study, 
prophylactic administration of pdFX to children aged <12 years main-
tained trough FX:C levels >5 IU/dL and resulted in a mean incremental 






(n = 2) All (N = 18) <12 years (n = 6) ≥12 years (n = 2) All (n = 8)
FX:C, IU/dL
Mean (SD) 9.4 (9.2) 29.5 (34.6) 11.6	(13.7) 67.7	(14.5) 103.0 (15.6) 76.5	(21.3)
Median (range) 6.0 (2.0- 40.0) 29.5 (5.0- 54.0) 6.0 (2.0- 54.0) 66.0 (46.0- 84.0) 103.0 (92.0– 114.0) 76.5	(46.0-	114.0)
Last weight, kg
Mean (SD) 13.1	(1.7) 65.8	(6.7) 18.9	(17.2) 11.5 (1.9) 60.4 (0.9) 23.7	(22.7)
Median (range) 14.0 (10.3- 14.0) 65.8	(61.0-	70.5) 14.0	(10.3–	70.5) 10.3 (10.3- 14.0) 60.35	(59.7-	61.0) 12.15 (10.3- 61.0)
Last dose, IU/kg
Mean (SD) 45.4	(7.1) 26.5	(2.7) 43.2 (9.2) 38.6 (11.6) 24.9 (0.4) 35.2	(11.7)
Median (range) 43.9 (24.3- 53.6) 26.5 (24.6- 28.4) 43.9 (24.3- 53.6) 42.1 (24.3- 48.5) 24.9 (24.6- 25.1) 30.9 (24.3- 48.5)
Time since last dose, days
Mean (SD) 3.2 (3.0) 3.5 (2.1) 3.2 (2.8) 0 0 0
Median (range) 3 (1- 14) 3.5 (2- 5) 3 (1- 14) 0 0 0
Abbreviations: FX:C, factor X activity; SD, standard deviation.
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recovery	 of	 1.74	 IU/dL.12 Although the current study was not de-
signed to determine incremental recovery, the lowest postdose FX:C 
recorded was 46.0. These results suggest that regular pdFX use in-
creases FX:C to a sufficient extent to prevent bleeds.
Investigators rated the overall efficacy of pdFX treatment during 
compassionate use as excellent for 14 of 15 patients and effective 
for the treatment of all individual bleeds. Similar results were ob-
served in a prospective study of 16 patients with moderate to se-
vere hereditary FXD receiving pdFX as on- demand treatment.10 
Patients rated pdFX treatment as successful for 98.4% of bleeds, 
and	investigators	rated	treatment	as	successful	for	97.6%	of	bleeds.	
Overall, investigators rated pdFX treatment as excellent in 80% of 
patients and good in 20%. Likewise, in a pediatric study of 9 children 
(aged <12 years) with moderate to severe hereditary FXD receiving 
6 months of prophylactic treatment, investigators rated the overall 
efficacy of pdFX as excellent. No adverse events related to pdFX 
treatment were observed in either study.10,12
At times, the patients in the current study also received pdFX 
for short- term prevention or perisurgical coverage. Although these 
doses were, on average, lower and less frequent than those ad-
ministered in the routine prophylaxis group, patients treated for 
short- term prevention or perisurgical coverage did not experience 
any bleeds. In an earlier study, five patients with mild to severe 
hereditary FXD undergoing surgery received pdFX both pre- and 
postoperatively.11 Again, investigators rated pdFX as excellent in 
preventing bleeds and achieving hemostasis; no blood transfusions 
were required and there were no ADRs.
Limitations of this study include the retrospective nature of the 
data collection, the small number of patients, the lack of a placebo 
control, and the variability in patient characteristics and treatments. 
Furthermore, comparisons of specific treatment regimens (ie, routine 
prophylaxis vs on- demand treatment) could not be made. However, 
these limitations are due to the low prevalence of hereditary FXD 
and the limited alternative treatment options available.
In this small retrospective study of patients with hereditary FXD, 
a rare disease, compassionate use of pdFX was safe and effective 
when used for routine prophylaxis, on- demand treatment, short- 
term prophylaxis, or perisurgical cover for the treatment of heredi-
tary FXD. Patients receiving routine prophylaxis experienced fewer 
bleeding episodes than those receiving on- demand treatment. No 
ADRs were observed, even with up to 4 years of treatment. These 
findings are consistent with previous prospective studies of pdFX 
and support the continued use of pdFX to treat patients with he-
reditary FXD.
ACKNOWLEDG MENTS
Bio Products Laboratory (Elstree, UK) provided funding for medical 
writing and editorial assistance in the development of this manu-
script. Mollie Marko, PhD (Ashfield MedComms, an Ashfield Health 
company, Middletown, CT, USA), drafted and revised the manu-
script based on input from authors, and Joshua Safran (Ashfield 
MedComms) copyedited and styled the manuscript per journal 
requirements.
AUTHOR CONTRIBUTIONS
CA was responsible for study concept and design. All authors con-
tributed to acquisition, analysis, and interpretation of data, oversaw 
the drafting of the manuscript, critically revised the manuscript for 
important intellectual content, and approved the manuscript for 
publication.
REL ATIONSHIP DISCLOSURE
JNH has received research funding from Baxter, Biogen, and Pfizer 
and has been a study investigator for Bio Products Laboratory. RL 
has been as a consultant and advisory board member for Baxalta, 
Bayer, Bio Products Laboratory, Novo Nordisk, Octapharma, 
Roche, and Sobi; has received honoraria from Baxalta Bayer, 
Novo Nordisk, Octapharma, Roche, and Sobi; and has been a re-
search funding recipient and speakers’ bureau participant for 
Baxalta, Bayer, Novo Nordisk, Octapharma, Roche, Sobi, and Sobi/
Bioverativ. CA is an employee of Bio Products Laboratory. SKA 
has been a consultant and advisory board member for Baxalta, 
Bayer, Bio Products Laboratory, CSL Behring, Novo Nordisk, 
Pfizer, and Sobi. KK has been a consultant to Baxalta, Bio Products 
Laboratory, CSL Behring, Novo Nordisk, and Octapharma; has re-
ceived honoraria from Baxalta, Bayer, Pfizer, and Shire; has been 
an advisory board member for Baxalta, Bayer, Novo Nordisk, 
Pfizer, and Shire; and has provided educational and investigational 
support to Baxalta, Bayer, Bio Products Laboratory, CSL Behring, 
Novo Nordisk, Octapharma, and Pfizer.
R E FE R E N C E S
 1. Brown DL, Kouides PA. Diagnosis and treatment of inherited factor 
X deficiency. Haemophilia.	2008;14(6):1176-	1182.
 2. Herrmann FH, Auerswald G, Ruiz- Saez A, et al. Factor X defi-
ciency: clinical manifestation of 102 subjects from Europe and 
Latin America with mutations in the factor 10 gene. Haemophilia. 
2006;12(5):479-	489.
 3. Peyvandi F, Mannucci PM, Lak M, et al. Congenital factor X defi-
ciency: spectrum of bleeding symptoms in 32 Iranian patients. Br J 
Haematol. 1998;102(2):626- 628.
 4. Bolton- Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagu-
lation disorders– review with guidelines for management from 
the United Kingdom Haemophilia Centre Doctors' Organisation. 
Haemophilia. 2004;10(5):593- 628.
 5. Peyvandi F, Di Michele D, Bolton- Maggs PH, et al. Classification of 
rare bleeding disorders (RBDs) based on the association between 
coagulant factor activity and clinical bleeding severity. J Thromb 
Haemost. 2012;10(9):1938- 1943.
 6. Giangrande P, Seitz R, Behr- Gross ME, et al. Kreuth III: European 
consensus proposals for treatment of haemophilia with coagulation 
factor concentrates. Haemophilia. 2014;20(3):322- 325.
	 7.	 National	 Hemophila	 Foundation.	 MASAC Recommendations 
Concerning Products Licensed for the Treatment of Hemophilia and 
Other Bleeding Disorders; 2020. https://www.hemop hilia.org/
sites/ defau lt/files/ docum ent/files/ 263_treat ment.pdf. Updated 
September 3, 2020.
 8. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diag-
nosis and management of the rare coagulation disorders: a United 
Kingdom Haemophilia Centre Doctors' Organization guideline on 
behalf of the British Committee for Standards in Haematology. Br J 
Haematol.	2014;167(3):304-	326.
    |  9 of 9HUANG et Al.
 9. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb 
Hemost.	2009;35(4):407-	415.
 10. Austin SK, Kavakli K, Norton M, et al. Efficacy, safety and pharma-
cokinetics of a new high- purity factor X concentrate in subjects with 
hereditary factor X deficiency. Haemophilia. 2016;22(3):419- 425.
 11. Escobar MA, Auerswald G, Austin S, Huang JN, Norton M, Millar 
CM. Experience of a new high- purity factor X concentrate in 
subjects with hereditary factor X deficiency undergoing surgery. 
Haemophilia.	2016;22(5):713-	720.
 12. Liesner R, Akanezi C, Norton M, Payne J. Prophylactic treatment 
of bleeding episodes in children <12 years with moderate to severe 
hereditary factor X deficiency (FXD): efficacy and safety of a high- 
purity plasma- derived factor X (pdFX) concentrate. Haemophilia. 
2018;24(6):941- 949.
 13. Kulkarni R, James AH, Norton M, Shapiro A. Efficacy, safety and 
pharmacokinetics of a new high- purity factor X concentrate in 
women and girls with hereditary factor X deficiency. J Thromb 
Haemost.	2018;16(5):849-	857.
 14. Coagadex® (Coagulation factor X [human]) [prescribing information]. 
Elstree, UK: Bio Products Laboratory Ltd; 2018.
 15. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activ-
ity and clinical bleeding severity in rare bleeding disorders: results 
from the European Network of Rare Bleeding Disorders. J Thromb 
Haemost. 2012;10(4):615- 621.
How to cite this article: Huang JN, Liesner R, Austin SK, 
Kavakli K, Akanezi C. Plasma- derived factor X concentrate 
compassionate use for hereditary factor X deficiency: 
Long- term safety and efficacy in a retrospective data- 
collection study. Res Pract Thromb Haemost. 2021;5:e12550. 
https://doi.org/10.1002/rth2.12550
